In the phase I clinical trial of treating locally advanced and metastatic solid tumors and HER2-expressing breast cancer with trastuzumab duocarmazine, an ORR of 6% was achieved in patients with gastric cancer, 25% in patients with urothelial cancer, and 39% in patients with endometrial cancer [29]. This evidence concerns the gene ERBB2 and breast cancer.